273 related articles for article (PubMed ID: 8348559)
1. Cytokine combinations in immunotherapy for solid tumors: a review.
Heaton KM; Grimm EA
Cancer Immunol Immunother; 1993 Sep; 37(4):213-9. PubMed ID: 8348559
[TBL] [Abstract][Full Text] [Related]
2. Cytokine-based therapy and biochemotherapy for advanced melanoma.
Atkins MB
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2353s-2358s. PubMed ID: 16609058
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2: solid-tumor therapy.
Oppenheim MH; Lotze MT
Oncology; 1994; 51(2):154-69. PubMed ID: 8196899
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
5. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
6. Cytokine-based Cancer Immunotherapy: Challenges and Opportunities for IL-10.
Rallis KS; Corrigan AE; Dadah H; George AM; Keshwara SM; Sideris M; Szabados B
Anticancer Res; 2021 Jul; 41(7):3247-3252. PubMed ID: 34230118
[TBL] [Abstract][Full Text] [Related]
7. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma.
van Herpen CM; De Mulder PH
Crit Rev Oncol Hematol; 2002 Mar; 41(3):327-34. PubMed ID: 11880208
[TBL] [Abstract][Full Text] [Related]
9. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Parton M; Gore M; Eisen T
J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials.
Atkins MB; Dutcher J; Weiss G; Margolin K; Clark J; Sosman J; Logan T; Aronson F; Mier J;
Med Oncol; 2001; 18(3):197-207. PubMed ID: 11917944
[TBL] [Abstract][Full Text] [Related]
12. The impact of cytokines on high dose chemotherapy followed by transplantation of purified and ex vivo expanded peripheral blood stem cells: achieving a state of minimal residual disease for tumor immunotherapy with cytokine gene transfected cells.
Mertelsmann R
Eur Cytokine Netw; 1995; 6(2):79-82. PubMed ID: 7578991
[No Abstract] [Full Text] [Related]
13. Combination of cytokines: current status and future prospects.
Kanz L; Brugger W; Bross K; Mertelsmann R
Br J Haematol; 1991 Oct; 79 Suppl 1():96-104. PubMed ID: 1931720
[TBL] [Abstract][Full Text] [Related]
14. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
15. Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.
Floros T; Tarhini AA
Semin Oncol; 2015 Aug; 42(4):539-48. PubMed ID: 26320059
[TBL] [Abstract][Full Text] [Related]
16. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.
Atzpodien J; Kirchner H
Klin Wochenschr; 1990 Jan; 68(1):1-11. PubMed ID: 2407894
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.
Rosenberg SA; Lotze MT; Yang JC; Linehan WM; Seipp C; Calabro S; Karp SE; Sherry RM; Steinberg S; White DE
J Clin Oncol; 1989 Dec; 7(12):1863-74. PubMed ID: 2685181
[TBL] [Abstract][Full Text] [Related]
18. The use of cytokines and chemokines in the cancer immunotherapy.
Amedei A; Prisco D; D' Elios MM
Recent Pat Anticancer Drug Discov; 2013 May; 8(2):126-42. PubMed ID: 22894642
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy.
Schuster M; Nechansky A; Kircheis R
Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
[TBL] [Abstract][Full Text] [Related]
20. Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
Xu DH; Zhu Z; Xiao H; Wakefield MR; Bai Q; Nicholl MB; Ding VA; Fang Y
Cancer Lett; 2017 May; 394():43-51. PubMed ID: 28254411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
